This may be good news … or it may not …

Barvarian Nordic has again delayed (slightly) when they expect to have the initial results of the Phase III clinical trial of Prostvac in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Two Phase III trials of PARP inhibitors in mCRPC

There are now two, ongoing, Phase III trials of PARP inhibitors in the treatment of eligible patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

State of the art lectures at the EAU meeting in London

Recently posted on the UroToday web site are summaries of four “state-of-the-art” lectures on prostate cancer and its management presented a couple of weeks ago at the annual meeting of the European Association of Urology is London. … READ MORE …

US-based, Phase II trial of lutetium-177 PSMA-directed endoradiotherapy

We have been provided (by the developers) with additional information about a US-based, Phase II, clinical trial of a form of radiation therapy using the targeted agent lutetium-177 prostate-specific membrane antigen 617 (177Lu-PSMA-617) for treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Results of Prostvac PROSPECT trial scheduled for later in 2017

According to Barvarian Nordic, the key results of the Phase III clinical trial of the immunologic agent Prostvac (rilimogene galvacirepvec/rilimogene glafolivec, or “rilimogene”) in treatment of metastatic, castration-resistant prostate cancer (mCRPC) are now expected in the second half of 2017. … READ MORE …

Data from the Phase III clinical trial of ipilimumab

Just over 3 years ago, Bristol-Myers Squibb announced that treatment with ipilimumab (Yervoy) had failed to show a survival benefit in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). For readers who may be interested, the data from this trial have finally been reported by Beer et al. in the Journal of Clinical Oncology.

Non-rising PSA but radiographic progression in men on treatment with enzalutamide

A recent presentation at the European Society of Medical Oncology (ESMO) annual meeting in Copenhagen, Denmark, has suggested that some men on treatment with enzalutamide (Xtandi) may have radiographic progression of their cancer even though there is no increase in their PSA levels. … READ MORE …